Orthofix (OFIX) executive sells 1,536 shares to cover RSU tax withholding

Rhea-AI Filing Summary

Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported selling 1,536 shares of common stock in open-market transactions on March 4 and 5, 2026 at weighted average prices of $12.9163 and $12.5508 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations under a pre-existing sell-to-cover requirement approved by a board committee and were executed without his discretionary choice. After these transactions, he held 50,633 shares and restricted stock units in total, including 41,134 previously reported restricted stock units.

Insights

Equity compensation analyst

Small, automatic sell-to-cover trades; routine equity tax event.

The transactions show Orthofix executive Patrick Fisher selling 1,536 shares of common stock at weighted average prices of $12.9163 and $12.5508 per share. The filing explains these sales were required to cover tax withholding from restricted stock unit settlements.

Because the sell-to-cover requirement was pre-approved by a board committee and executed without the executive’s discretion, this looks like standard equity compensation administration rather than a discretionary reduction in exposure. After the trades, he still holds 50,633 shares and units, including 41,134 restricted stock units, indicating continued alignment with shareholders.

Insider Trade Summary

Net Seller: 1,536 shares ($19,562)

Net Sell 2 txns

Insider Fisher Patrick

Role President, Global Limb Recon

Sold 1,536 shs ($20K)

Type	Security	Shares	Price	Value
Sale	Common Stock	758	$12.5508	$10K
Sale	Common Stock	778	$12.9163	$10K

Holdings After Transaction: Common Stock — 50,633 shares (Direct)

Footnotes (1)

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. Includes 41,134 previously reported restricted stock units The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisher Patrick

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Global Limb Recon

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		778	D	$12.9163(2)	51,391(3)	D
Common Stock	03/05/2026		S(1)		758	D	$12.5508(4)	50,633(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

3. Includes 41,134 previously reported restricted stock units

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

	/s/ J. Andres Cedron, Attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Orthofix Medical (OFIX) report for Patrick Fisher?

Orthofix Medical reported that executive Patrick Fisher sold 1,536 shares of common stock in two open-market transactions. These sales occurred on March 4 and 5, 2026, at weighted average prices of $12.9163 and $12.5508 per share, respectively, according to the disclosure.

Why did Patrick Fisher sell Orthofix Medical (OFIX) shares in this Form 4 filing?

The filing states the shares were sold to satisfy tax withholding obligations from restricted stock unit settlements. The sales occurred under a pre-existing sell-to-cover requirement approved by a board committee and were executed without discretionary choice by Patrick Fisher, indicating a routine compensation-related event.

How many Orthofix Medical (OFIX) shares did Patrick Fisher sell and at what prices?

Patrick Fisher sold a total of 1,536 Orthofix Medical common shares. He sold 778 shares at a weighted average price of $12.9163 on March 4, 2026, and 758 shares at a weighted average price of $12.5508 on March 5, 2026, in open-market transactions.

How many Orthofix Medical (OFIX) shares does Patrick Fisher hold after these transactions?

After the reported transactions, Patrick Fisher beneficially owned 50,633 Orthofix-related shares and units. This total includes 41,134 previously reported restricted stock units, indicating that most of his reported position is in unvested or unsettled equity awards rather than freely tradable common stock.

Were Patrick Fisher’s Orthofix Medical (OFIX) stock sales discretionary trades?

The disclosure explains these sales were made pursuant to a pre-existing sell-to-cover requirement approved by a board committee. They were executed to cover tax withholding on restricted stock unit settlements and completed without any discretionary decision-making by Patrick Fisher regarding timing or amount sold.

What do the weighted average prices in Patrick Fisher’s Orthofix Medical (OFIX) sales mean?

The reported prices of $12.9163 and $12.5508 are weighted averages across multiple trades within specified price ranges. The filing notes the shares on March 4 traded between $12.80 and $13.03, and on March 5 traded between $12.48 and $12.72, with detailed breakdowns available on request.